Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Mechanismen van voordeel van IL4RA-remming bij door aspirine verergerde luchtwegaandoeningen (MARINER)

21 oktober 2026 bijgewerkt door: Tanya Laidlaw, MD, Brigham and Women's Hospital

Voordeelmechanismen van IL4RA-remming bij door aspirine verergerde luchtwegaandoeningen: MARINER

The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).

Studie Overzicht

Gedetailleerde beschrijving

The protocol involves an 8-week study of dupilumab in patients with CRSwNP and/or AERD. Participants will have 4 total doses of dupilumab administered, with each dose administered every 2 weeks. There will be full clinical assessments and biospecimen collections at Baseline (Visit 1), Week 2 (Visit 2), and Week 8 (Visit 3).

Studietype

Ingrijpend

Inschrijving (Werkelijk)

17

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02115
        • Brigham and Women's Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Key Inclusion Criteria:

  1. History of AERD, defined as meeting the diagnostic triad with:

    1. History of physician-diagnosed asthma and
    2. History of physician-diagnosed nasal polyposis and
    3. History of pathognomonic reactions to aspirin or other nonselective COX inhibitors.
  2. Visible nasal polyps bilaterally on otoscope physical exam at the time of screening.

  3. Evidence of sense of smell impairment, with a University of Pennsylvania Smell Identification Test (UPSIT) score of <34.

  4. Stable asthma (no glucocorticoid burst for at least 4 weeks prior to Visit 1, and no hospitalizations or ER visits for asthma for at least the prior 3 months).

  5. Consistent (daily) use of an intranasal steroid for at least 4 weeks prior to Screening.

  6. No current smoking (not more than one instance of smoking in the last 3 months).

  7. For females: Practicing FDA-approved methods of birth control for the duration of the study. Female participants of childbearing potential must have a negative pregnancy test upon study entry.

Key Exclusion Criteria:

  1. Use of investigational drugs within 12 weeks of Screening.
  2. Use of any biologic agent within 4 months prior to Screening.
  3. Use of systemic (enteral or injected) glucocorticoids within 4 weeks prior to Screening.
  4. History of any sinonasal surgery within 4 months prior to Screening
  5. Current use of zileuton
  6. Current use of high-dose aspirin therapy (no more than 325 mg aspirin per day will be allowed)
  7. Pregnant, nursing, or planning to become pregnant

Note: Other inclusion and exclusion criteria apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Dupilumab

Subjects will receive dupilumab (300mg every-other-week for 8 weeks).

8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.

Andere namen:
  • Dupilumab voorgevulde spuit [Dupixent]

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Nasal Fluid Levels of LTE4
Tijdsspanne: At Week 8 (Visit 3)

The nasal fluid levels of LTE4 will be measured at week 8 and will serve as a surrogate biomarker of respiratory mast cell activation or burden.

At Week 8 (Visit 3)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Nasal Fluid Levels of Albumin
Tijdsspanne: At Week 8 (Visit 3)

The nasal fluid levels of albumin will be measured at week 8 and serve as a surrogate biomarker of nasal epithelial cell integrity.

At Week 8 (Visit 3)
Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Tijdsspanne: At Week 8 (Visit 3)

Patients' sense of smell will be assessed at week 8 using the UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)

At Week 8 (Visit 3)
Rhinoscopic Total Polyp Score (TPS)
Tijdsspanne: At Week 8 (Visit 3)

The extent of patients' nasal polyps will be assessed at week 8 using a TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.

At Week 8 (Visit 3)
Peak Nasal Inspiratory Flow (PNIF)
Tijdsspanne: At Week 8 (Visit 3)

Patients' nasal congestion will be assessed at week 8 by a PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.

At Week 8 (Visit 3)
Quality of Life - 22-Item Sino-Nasal Outcome Test (SNOT-22)
Tijdsspanne: At Week 8 (Visit 3)

Quality of life will be assessed at week 8 with a SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).

At Week 8 (Visit 3)
Lung Function - Forced Expiratory Volume 1 (FEV1)
Tijdsspanne: At Week 8 (Visit 3)

Patients' lung function will be assessed at week 8 with an FEV1.

At Week 8 (Visit 3)
Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Tijdsspanne: At Week 8 (Visit 3)

Asthma control will be measured at week 8 with an ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.

At Week 8 (Visit 3)
Number of Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs) Leading to Study Drug Discontinuation
Tijdsspanne: At Week 8 (Visit 3)

Safety will be measured by the number of treatment-related AEs and SAEs leading to dupilumab discontinuation.

At Week 8 (Visit 3)

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Sense of Smell - University of Pennsylvania Smell Identification Test (UPSIT)
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in UPSIT. The UPSIT scale goes from 0 to 40, with 0 being worse (no scents identified) and 40 being best (all scents identified)

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Rhinoscopic Total Polyp Score (TPS)
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in TPS. The TPS scale goes from 0 (no polyps) to 8 (large polyps bilaterally), with 0 being best and 8 being worst.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Peak Nasal Inspiratory Flow (PNIF)
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in PNIF. PNIF goes from 0 mL (no airflow) to 500 mL of airflow, with 0 being worst.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in 22-Item Sino-Nasal Outcome Test (SNOT-22)
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in SNOT-22. For the SNOT-22, the scores range from 0 (no symptoms, excellent disease control) to 110 (maximum sinus symptoms, poor disease control).

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Lung Function - Forced Expiratory Volume 1 (FEV1)
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in FEV1.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Asthma Control - Asthma Control Questionnaire-6 (ACQ-6)
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in ACQ-6. For the ACQ-6, scores ranging from 0 (well-controlled) to 6 (extremely poorly-controlled). A lower score indicates better asthma control.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Nasal Fluid Levels of Eicosanoids
Tijdsspanne: weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid eicosanoid levels.

weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Nasal Fluid Levels of Albumin
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid albumin levels.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Urinary Levels of Eicosanoids
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in urinary eicosanoid levels.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Serum Tryptase
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in serum tryptase levels.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in IgE Levels
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid and plasma levels of IgE.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)
Change in Eosinophilic Cationic Protein (ECP)
Tijdsspanne: 2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Change from Visit 1 to Visit 2 and from Visit 1 to Visit 3 in nasal fluid levels of ECP.

2 weeks (between Visit 1 and Visit 2) and 8 weeks (between Visit 1 and Visit 3)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Tanya M Laidlaw, MD, Brigham and Women's Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 augustus 2023

Primaire voltooiing (Werkelijk)

30 april 2026

Studie voltooiing (Geschat)

30 december 2026

Studieregistratiedata

Eerst ingediend

7 oktober 2022

Eerst ingediend dat voldeed aan de QC-criteria

7 oktober 2022

Eerst geplaatst (Werkelijk)

12 oktober 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

21 oktober 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren